<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998841</url>
  </required_header>
  <id_info>
    <org_study_id>GN28352</org_study_id>
    <nct_id>NCT01998841</nct_id>
  </id_info>
  <brief_title>A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Banner Alzheimer's Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo-controlled, parallel group, adaptive study will
      evaluate the efficacy and safety of crenezumab versus placebo in individuals who carry the
      PSEN1 E280A autosomal-dominant mutation and do not meet the criteria for mild cognitive
      impairment due to AD or dementia due to AD and are, thus, in a preclinical phase of AD.
      Participants will be randomized in a 1:1 ratio to receive either crenezumab or placebo
      subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks. The
      switch to the intravenous (IV) dose will be optional (as per participant decision). The study
      will also include a cohort of PSEN1 E280A mutation non-carriers who will be dosed with
      placebo only.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 20, 2013</start_date>
  <completion_date type="Anticipated">February 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease (API ADAD) Composite Cognitive Test Total Score at Week 260</measure>
    <time_frame>Baseline and Week 260</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression to Mild Cognitive Impairment (MCI) due to AD or to Dementia due to AD</measure>
    <time_frame>Baseline up to 260 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Dementia Rating (CDR) Scale Global Score of Greater Than (&gt;) Zero</measure>
    <time_frame>Baseline up to 260 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDR Scale - Sum of Boxes at Week 260</measure>
    <time_frame>Baseline and Week 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Episodic Memory Measure: Free and Cued Selective Reminding Task (FCSRT) at Week 260</measure>
    <time_frame>Baseline and Week 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Measure of Overall Neurocognitive Functioning: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at Week 260</measure>
    <time_frame>Baseline and Week 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Cerebral Fibrillar Amyloid Accumulation Standard Uptake Value Ratio (SUVR) as Assessed by Positron Emission Tomography (PET) at Week 260</measure>
    <time_frame>Baseline and Week 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Regional Cerebral Metabolic Rate of Glucose (CMRgI) Using Fluorine-18-Labeled 2-Deoxyglucose (FDG)-PET at Week 260</measure>
    <time_frame>Baseline and Week 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Brain Atrophy Measured by Volumetric Measurements Using Magnetic Resonance Imaging (MRI) at Week 260</measure>
    <time_frame>Baseline and Week 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in a tau-Based Cerebral Spinal Fluid (CSF) Biomarker at Week 260</measure>
    <time_frame>Baseline and Week 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 up to 16 weeks following the last administration of study drug or study discontinuation/termination, whichever is later (up to approximately 432 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-Crenezumab Antibodies</measure>
    <time_frame>Day 1 up to 16 weeks following the last administration of study drug or study discontinuation/termination, whichever is later (up to approximately 432 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF Crenezumab Concentration</measure>
    <time_frame>Baseline (at least 72 hours prior to the first study drug administration); Weeks 104 and 260; at study completion/early discontinuation (up to approximately 416 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Crenezumab Concentration</measure>
    <time_frame>Predose (Hour 0) at Baseline, Weeks 4, 12, 16, 24, 36, 52, 76, 104, 128, 156, 180, 208, 232, 260, 284, 312, 336, 364, 388, 416, and 16 weeks after last dose/early discontinuation (up to approximately 432 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">252</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Mutation Carriers: Crenezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive crenezumab subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mutation Carriers: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-carriers of Mutation: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crenezumab</intervention_name>
    <description>Crenezumab will be administered subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.</description>
    <arm_group_label>Mutation Carriers: Crenezumab</arm_group_label>
    <other_name>MABT5102A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to crenezumab will be administered subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.</description>
    <arm_group_label>Mutation Carriers: Placebo</arm_group_label>
    <arm_group_label>Non-carriers of Mutation: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Membership in PSEN1 E280A mutation carrier kindred

          -  Agrees to conditions of, and is willing to undergo, genetic testing (for example
             [e.g.], apolipoprotein E [APOE], PSEN1 E280A, and other genetic testing)

          -  PSEN1 E280A mutation carrier or non-carrier status has been confirmed prior to or
             during the screening period

          -  Mini-Mental Stage Examination (MMSE) greater than or equal to (&gt;=) 24 for participants
             with less than (&lt;) 9 years of education or MMSE &gt;=26 for participants with 9 or more
             years of education

          -  Does not meet criteria for dementia due to AD per the National Institute on Aging and
             the Alzheimer's Association Workgroup (McKhann et al. 2011) criteria

          -  Does not meet criteria for mild cognitive impairment (MCI) due to AD per the National
             Institute on Aging and the Alzheimer's Association Workgroup (Albert et al. 2011)
             criteria

          -  Adequate vision and hearing in the investigator's judgment to be able to complete
             testing

          -  If female, and not documented (by medical records or physician's note) to be
             surgically sterile (absence of ovaries and/or uterus) or postmenopausal, willing to
             undergo pregnancy tests at protocol-specific timepoints

          -  For women who are not documented (by medical records or physician's note) to be
             surgically sterile (absence of ovaries and/or uterus) or postmenopausal, agreement to
             remain abstinent or use two adequate methods of contraception, including at least one
             method with a failure rate of &lt;1 percent (%) per year (e.g., hormonal implants,
             combined oral contraceptives, vasectomized partner, tubal ligation) during the
             treatment period and for at least 16 weeks after the last dose of study drug

          -  For men with partners of childbearing potential (that is [i.e.], women who are not
             surgically sterile and are not postmenopausal), agreement to remain abstinent or use a
             condom as a method of contraception during the treatment period and for at least 8
             weeks after the last dose of study drug

          -  Study partner who agrees to participate in the study and is capable of and willing to:
             accompany the participant to all required visits; provide information for required
             telephone assessments; spend sufficient time with the participant to be familiar with
             his/her overall function and behavior and be able to provide adequate information
             about the participant including knowledge about domestic activities, hobbies,
             routines, social skills and basic activities of daily life; work and educational
             history; cognitive performance including memory abilities, language abilities,
             temporal and spatial orientation, judgment and problem solving; emotional and
             psychological state; and general health status

          -  Participant and study partner have evidence of adequate premorbid functioning (e.g.,
             intellectual, visual, and auditory) and are fluent in, and able to read, the language
             in which study assessments are administered

          -  Willing and able to undergo neuroimaging (PET and MRI)

          -  Serum thyroid stimulating hormone (TSH) and B12 levels within normal or expected
             ranges for the testing laboratory or if TSH and B12 values are out of range they are
             judged by the investigator not to be clinically significant. If participant is
             undergoing thyroid replacement therapy, TSH levels must be within normal or expected
             ranges for the testing laboratory or, if TSH values are out of range, they do not
             require any therapeutic actions (treatment or surveillance). If participant is
             receiving vitamin B12 injections or oral vitamin B12 therapy, B12 levels must be at or
             above the lower limit of normal for the testing laboratory or, if B12 values are out
             of range, they do not require any therapeutic actions (treatment or surveillance)

          -  In good general health with no known co-morbidities expected to interfere with
             participation in the study

        Exclusion Criteria:

          -  Significant medical, psychiatric, or neurological condition or disorder documented by
             history, physical, neurological, laboratory, or electrocardiogram (ECG) examination
             that would place the participant at undue risk in the investigator's judgment or
             impact the interpretation of efficacy

          -  History of stroke. Participants with a history of transient ischemic attack may be
             enrolled if the event occurred &gt;=2 years prior to screening

          -  History of severe, clinically significant (persistent neurological deficit or
             structural brain damage) central nervous system trauma (e.g. cerebral contusion)

          -  Body weight &lt;45 or &gt;120 kilograms (kg)

          -  History or presence of atrial fibrillation that poses a risk for future stroke in the
             investigator's judgment

          -  Clinically significant laboratory or ECG abnormalities (e.g., abnormally prolonged or
             shortened QTc interval) in the investigator's judgment

          -  Current presence of bipolar disorder or other clinically significant major psychiatric
             disorder according to Diagnostic and Statistical Manual of Mental Disorders 4th
             Edition Text Revision (DSM-IV-TR) or symptom (e.g., hallucinations, agitation,
             paranoia) that could affect the participant's ability to complete evaluations

          -  Clinically significant depression, based in part by a Geriatric Depression Scale
             (short form) (15-point scale) score &gt;9 at screening

          -  History of seizures (excluding febrile seizures of childhood, or other isolated
             seizure episodes that were not due to epilepsy in the judgment of the investigator,
             and required at most time-limited anticonvulsant treatment, and which occurred more
             than 7 years prior to the screening visit)

          -  Myocardial infarction within 2 years, congestive heart failure, atrial fibrillation,
             or uncontrolled hypertension

          -  Pregnant or nursing women, or women who intend to become pregnant or to nurse infants
             during the conduct of this trial

          -  Clinically significant infection within the last 30 days prior to screening

          -  Positive urine test for drugs of abuse at screening

          -  History of alcohol or substance dependence within the previous two years

          -  Use of any other medications with the potential to significantly affect cognition;
             intermittent or short-term use of these medications may be allowed if deemed medically
             necessary for the treatment of a non-excluded medical condition with approval from the
             Medical Monitor. In addition, use of tricyclic antidepressants or benzodiazepines will
             be permitted if used in stable, low doses for the treatment of a non-excluded medical
             condition with approval from the Medical Monitor

          -  Use of typical anti-psychotics or barbiturates

          -  Use of non-anti-cholinergic antidepressant medications or atypical anti-psychotics
             unless maintained on a stable dose regimen for at least 6 weeks prior to screening

          -  Use of any Food and Drug Administration (FDA)/Instituto Nacional de Vigilancia de
             Medicamentos y Alimentos (INVIMA)-approved medications for treatment of late onset
             Alzheimer's disease (LOAD) at screening/baseline. Cholinesterase inhibitors and/or
             memantine are prohibited during the study except in participants enrolled in the study
             that develop AD dementia

          -  Use of anti-coagulant medication (heparinoids, heparin, warfarin, thrombin inhibitors,
             Factor Xa inhibitors), or known coagulopathy or platelet count &lt;100,000
             cells/microliter, within 4 weeks of the screening visit; Anti-platelet medications
             (e.g., aspirin, clopidigrel, dipyridamole) are permitted if on a stable dose for 4 or
             more weeks prior to screening. Short-term, peri-operative use of anti-coagulants may
             not result in discontinuation from the study; however, any such use must be discussed
             with the Medical Monitor

          -  Treatment with any biologic therapy within five half-lives or 3 months prior to
             screening, whichever is longer, with the exception of routinely recommended
             vaccinations, which are allowed

          -  Use of anti-seizure medication (except in childhood for febrile seizures or if used
             for non-seizure indications), anti-parkinsonian, or stimulant (e.g., methylphenidate)
             medications

          -  Use of investigational drug, device, or experimental medication within 60 days (or
             five half-lives, whichever is longer) of the screening visit

          -  Previous treatment with crenezumab or any other therapeutic that targets A-beta

          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric, human, or humanized antibodies or fusion proteins

          -  Contraindication to MRI scan procedures or clinically significant claustrophobia that
             would contraindicate a brain MRI scan

          -  Contraindication to PET scan procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundacion Cardiomet</name>
      <address>
        <city>Armenia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cl√≠nica de Marly</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grupo Neurociencias de Antioquia</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan de Dios</name>
      <address>
        <city>Yarumal</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2013</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

